Progenitor-like exhausted SPRY1

Humans Esophageal Squamous Cell Carcinoma / genetics CD8-Positive T-Lymphocytes Programmed Cell Death 1 Receptor Esophageal Neoplasms / drug therapy Neoadjuvant Therapy Biomarkers Tumor Microenvironment Membrane Proteins / genetics Phosphoproteins
T cell exhaustion anti-PD-1 complete response esophageal squamous cell carcinoma neoadjuvant immune checkpoint blockade tumor microenvironment

Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
13 11 2023
Historique:
received: 03 01 2023
revised: 15 08 2023
accepted: 18 09 2023
medline: 16 11 2023
pubmed: 14 10 2023
entrez: 13 10 2023
Statut: ppublish

Résumé

Neoadjuvant immune checkpoint blockade (ICB) demonstrates promise in operable esophageal squamous cell carcinoma (ESCC), but lacks available efficacy biomarkers. Here, we perform single-cell RNA-sequencing of tumors from patients with ESCC undergoing neoadjuvant ICB, revealing a subset of exhausted CD8

Identifiants

DOI: 10.1016/j.ccell.2023.09.011 PMID: 37832554
pubmed: 37832554
pii: S1535-6108(23)00327-6
doi: 10.1016/j.ccell.2023.09.011
pii:
doi:

Substances chimiques

Programmed Cell Death 1 Receptor 0
Biomarkers 0
SPRY1 protein, human 0
Membrane Proteins 0
Phosphoproteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1852-1870.e9

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests B.K. serves as the speaker and advisory board for AstraZeneca, Merck, Medtronic. F.D. received research support to the institution from Amgen, Astrazeneca, BMS, Exelixis, Genentech, Ipsen, Signatera, Taiho; has received consulting fees from Astrazeneca, Eisai, Exelixis, Genentech, Foundation Medicine, Ipsen and served on the speakers bureau for Amgen, Deciphera, Eisai, Exelixis, Ipsen, Servier, Signatera, Sirtex. F.D.’s spouse is employed by Roche Diagnostics U.S.

Auteurs

Zhichao Liu (Z)

Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai 200030, China.

Yaru Zhang (Y)

School of Biomedical Engineering, School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China; Oujiang Laboratory, Zhejiang Lab for Regenerative Medicine, Vision and Brain Health, Wenzhou, Zhejiang 325101, China.

Ning Ma (N)

Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai 200030, China.

Yang Yang (Y)

Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai 200030, China.

Yunlong Ma (Y)

School of Biomedical Engineering, School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.

Feng Wang (F)

State Key Laboratory of Oncogenes and Related Genes, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.

Yan Wang (Y)

Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China.

Jinzhi Wei (J)

Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.

Hongyan Chen (H)

State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Alfredo Tartarone (A)

Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (PZ) 85028, Italy.

Jeffrey B Velotta (JB)

Department of Thoracic Surgery, Kaiser Permanente Oakland Medical Center, Kaiser Permanente Northern California, Oakland, CA 94611, USA.

Farshid Dayyani (F)

Chao Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA.

Emmanuel Gabriel (E)

Department of Surgery, Division of Surgical Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.

Connor J Wakefield (CJ)

Department of Internal Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA.

Biniam Kidane (B)

Section of Thoracic Surgery, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.

Cristiano Carbonelli (C)

Pneumology Unit, Department of Medical Sciences, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo 71013, Italy.

Lingyun Long (L)

CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China. Electronic address: lylong@sinh.ac.cn.

Zhihua Liu (Z)

State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address: liuzh@cicams.ac.cn.

Jianzhong Su (J)

School of Biomedical Engineering, School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China; Oujiang Laboratory, Zhejiang Lab for Regenerative Medicine, Vision and Brain Health, Wenzhou, Zhejiang 325101, China. Electronic address: sujz@wmu.edu.cn.

Zhigang Li (Z)

Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai 200030, China. Electronic address: zhigang.li@shsmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Progenitor-like exhausted SPRY1
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Tumeurs gastro-intestinales › Tumeurs de l'oesophage › Carcinome épidermoïde de l'oesophage › Progenitor-like exhausted SPRY1
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Progenitor-like exhausted SPRY1
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › Progenitor-like exhausted SPRY1
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Tumeurs gastro-intestinales › Tumeurs de l'oesophage › Progenitor-like exhausted SPRY1
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Traitement néoadjuvant › Progenitor-like exhausted SPRY1
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Progenitor-like exhausted SPRY1
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Progenitor-like exhausted SPRY1
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Progenitor-like exhausted SPRY1
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Progenitor-like exhausted SPRY1